Bayer-sponsored and Collaborative
Clinical Trials
Explore the details of our ongoing clinical trials to learn whether you have patients who may be ideal candidates for any of our currently enrolling or soon-to-be-enrolling trials.
Colorectal Cancer
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3Ka Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Esophageal, Pancreatic) | I | Now Enrolling | A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation | |
Solid Tumors, Gastrointestinal Cancer (Colorectal) | I | Now Enrolling | A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | |
Gastrointestinal Cancer (Colorectal) | II | Now Enrolling | A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum |
Esophageal Cancer
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Esophageal, Pancreatic) | I | Now Enrolling | A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation |
Pancreatic Cancer
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Esophageal, Pancreatic) | I | Now Enrolling | A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation | |
Solid Tumors, Gastrointestinal Cancer (Pancreatic) | I, II | Now Enrolling | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors |
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Lung Cancer, Solid Tumors, Head and Neck Cancer | I | Now Enrolling | A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors |
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Liver Cancer | I | Now Enrolling | A Multicenter, Open Label, Non-randomized First-in-human Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BAY 3547926 Alone, and in Combination, in Participants With Advanced Hepatocellular Carcinoma (HCC) (BANTAM-01) |
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Lung Cancer, Solid Tumors, Head and Neck Cancer | I | Now Enrolling | A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Esophageal, Pancreatic) | I | Now Enrolling | A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation | |
Lung Cancer | I, II | Now Enrolling | An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non–small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation | |
Lung Cancer | III | Now Enrolling | A Phase 3 Open-Label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-Line Therapy in Patients With Locally Advanced or Metastatic Non–small Cell Lung Cancer (NSCLC) With HER2-Activating Mutations |
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Prostate Cancer | I | Now Enrolling | A Phase 1 Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of 225Ac-PSMA-Trillium in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA) | |
Prostate Cancer | III | Active, Not Enrolling | Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) | |
Prostate Cancer | III | Active, Not Enrolling | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP) | |
Prostate Cancer | III | Active, Not Enrolling | An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies | |
Prostate Cancer | III | Active, Not Enrolling | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer | |
Prostate Cancer | Non-interventional Study | Active, Not Enrolling | Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients | |
Prostate Cancer | Non-interventional Study | Now Enrolling | A Multicenter, Real-world Study Evaluating the Effectiveness of Darolutamide Plus ADT in Patients Progressing to nmCRPC After Bicalutamide Plus ADT Treatment During nmHSPC Stage | |
Prostate Cancer | Non-interventional Study | Now Enrolling | Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients | |
Prostate Cancer | Non-interventional Study | Now Enrolling | An Observational Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Low-volume Metastatic Hormone-sensitive Prostate Cancer | |
Prostate Cancer | Non-interventional Study | Active, Not Enrolling | ROAD - Real-World Outcomes of Darolutamide, ADT, With or Without Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer |
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Lung Cancer, Solid Tumors, Head and Neck Cancer | I | Now Enrolling | A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors | |
Solid Tumors, Gastrointestinal Cancer (Colorectal) | I | Now Enrolling | A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Esophageal, Pancreatic) | I | Now Enrolling | A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation | |
Solid Tumors, Gastrointestinal Cancer (Pancreatic) | I, II | Now Enrolling | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors | |
Solid Tumors | I, II | Active, Not Enrolling | A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors | |
Solid Tumors | II | Now Enrolling | A Phase 2 Open-Label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-Activating Mutations | |
Solid Tumors | Non-interventional Study | Now Enrolling | Prospective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib | |
Solid Tumors | Non-interventional Study | Now Enrolling | Special Drug Use Investigation for Larotrectinib |
Bayer’s Oncology Pipeline Brochure
Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.
The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.